In breast cancer, both growth promoting and inhibitory effects of morphine on tumour cells have been reported [40, 41] and the common A118G genetic polymorphism in the MOR that is linked to reduced analgesic response has, contradictorily, been correlated with both decreased breast cancer-specific mortality [42] and increased breast cancer incidence [43]. This evidence concerns the gene OPRM1 and neoplasm.